Akari Therapeutics (AKTX) Total Non-Current Liabilities (2011 - 2026)

Akari Therapeutics (AKTX) has reported Total Non-Current Liabilities for 12 consecutive years, with $19.5 million the latest figure, recorded in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 32.66% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.5 million (down 32.66% YoY) and the FY2025 annual result came in at $19.3 million, down 30.83% from the prior year.
• Total Non-Current Liabilities advanced to $19.5 million in Q1 2026 per AKTX's latest filing, from $19.3 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for AKTX reached as high as $28.9 million in Q1 2025 and fell as low as $2.6 million in Q3 2024.
• A 5-year average of $13.7 million and a median of $12.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2025 — Total Non-Current Liabilities surged 983.35% — and 2026, when it plunged 32.66%.
• Year by year, Total Non-Current Liabilities stood at $4.2 million in 2022, then slipped by 20.48% to $3.3 million in 2023, then surged by 739.09% to $28.0 million in 2024, then tumbled by 30.83% to $19.3 million in 2025, then advanced by 0.82% to $19.5 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $19.5 million, $19.3 million, and $22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.